Navigation Links
New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry
Date:7/23/2014

WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA).

Logo - http://photos.prnewswire.com/prnh/20140723/129680

Required by the Food and Drug Administration (FDA) for certain small-molecule drugs and biologics, REMS programs are intended to improve drug safety by ensuring that the benefits for patients outweigh the risks. However, new survey results indicate that brand drug manufacturers use REMS programs and other distribution restrictions to prevent generic drug manufacturers from accessing drug samples. Because a generic drug manufacturer must test a product it is developing against a sample of the brand drug to ensure bioequivalence, this obstruction delays generic market entry and the savings generic drugs offer.

"Nearly 40 percent of new FDA drug approvals are now subject to REMS," noted Alex Brill, CEO of MGA and author of the study. "The lost savings arising from misuse of these programs has a direct effect on the cost of health care for consumers, private payors, and government."

The MGA analysis, sponsored by the Generic Pharmaceutical Association, examines forty small-molecule drugs that a survey of generic companies identified as restricted. Using U.S. sales, utilization, and price data from IMS Health, MGA estimates that the delayed market entry of generics for these products results in annual lost savings of $5.4 billion. Of this, the federal government bears a third of the burden, or $1.8 billion. Private insurance companies lose $2.4 billion, and consumers pay $960 million in extra out-of-pocket costs. State and local governments and other small payors lose savings of $240 million.

REMS misuse can be expected to extend to biosimilars once the FDA provides final guidance for biosimilars to enter the market. MGA estimates that delayed biosimilar entry from restricted access to biologics samples would result in approximately $140 million in lost savings for every $1 billion in biologics sales. In 2013, U.S. biologics sales totaled approximately $92 billion, or 28 percent of U.S. drug spending that year.

ABOUT MGA

Matrix Global Advisors (MGA) is a Washington, DC-based economic consulting firm led by Alex Brill. MGA engages in consulting and analysis on a range of health care, tax, and other policy matters. Prior to founding MGA, Brill served as policy director and chief economist to the House Ways and Means Committee and on the staff of the White House Council of Economic Advisers.

For media inquiries, please contact Jonathan Toomey at 202-558-7159.

Media Contact: Jonathan Toomey, Matrix Global Advisors, 202-558-7159, jtoomey@matrixglobaladvisors.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Matrix Global Advisors
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
2. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
3. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
4. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
5. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
6. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Demand for Product Pipeline Review and Analysis Rises in the Global Pharma Industry
8. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
9. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
10. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
11. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...   ZappRx, Inc ., a digital health company focused ... announced it closed $25 million in Series B funding led ... in Seattle that is part of ... Series B round included participation from SR One , ... GV (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 2017 , ... Donna Parker, L. Ac. reads all sorts of books on ... to be very practical. She wanted to write a guide/workbook that would give readers ... It prompted her in writing “ A Clear Path to a Vibrant Life : ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is ... the process rendered in my Art and Music. These are created as Metaphysical Transformations ... the boundary of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... ... to his role as Vice President of Sales and Business Development at OAKWORKS, ... GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary ... that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright ... people involved in violence in the United States. The study, Trends in ...
Breaking Medicine News(10 mins):